A four-author clinical review from major US academic centers sorts the marketing from the medicine on magnesium. The verdict is a clean split. Frank biochemical deficiency is rare, but subclinical or functional shortfall is common, and more than half of US adults eat less than the recommended amount. Randomized trials genuinely support magnesium for constipation, reflux, depression, migraine prevention, type 2 diabetes control, and blood pressure in specific high-risk groups, plus emergency intravenous use in eclampsia, torsades, and severe asthma. But the trendy consumer claims for sleep, muscle cramps, athletic recovery, brain longevity, and general anti-aging rest on thin, heterogeneous, or purely observational evidence. The purported longevity benefit, the reason many biohackers buy it, has essentially no clinically meaningful human endpoint data behind it.
Magnesium is having a marketing moment. The global supplement market for the mineral hit roughly 53 million dollars in 2025 and is projected to reach 81 million by 2033, and scroll through any wellness feed and you will be told magnesium fixes your sleep, your anxiety, your workouts, and your aging cells. A new review in Current Nutrition Reports takes that pitch apart with a scalpel, and the picture that emerges is more honest than most supplement labels.
Start with what is real. Magnesium is a cofactor in over 300 enzymatic reactions, from ATP production to DNA synthesis, so a genuine shortfall matters. Overt, lab-confirmed deficiency is uncommon, but a quieter functional insufficiency appears widespread, partly because modern fruits and vegetables carry less magnesium than they used to. The authors reserve their confidence for outcomes tested in randomized controlled trials. Poorly absorbed magnesium salts are effective osmotic laxatives, with magnesium oxide carrying the strongest evidence for chronic constipation. Magnesium supplementation modestly improves depression scores and cuts migraine frequency. In people with type 2 diabetes it nudges down HbA1c, insulin resistance, and blood pressure. And intravenous magnesium sulfate remains a genuine emergency drug, halving eclampsia risk in the landmark Magpie trial.
Now the hype. The claims driving much of the consumer boom, better sleep, fewer muscle cramps, faster athletic recovery, sharper aging brains, and longer life, are where the evidence thins to a whisper. Sleep studies are heterogeneous and high risk of bias. The much-marketed magnesium L-threonate for brain health rests largely on rodent work and a single small twelve-week human trial. On aging specifically, the authors are blunt. Magnesium is mechanistically linked to several hallmarks of aging, but clinically meaningful human endpoints simply do not exist, and short trials cannot speak to lifespan.
The take-home is unglamorous. Magnesium is a legitimate therapeutic in defined clinical situations and a sensible dietary target, not a longevity elixir. The authors also flag real risk: in people with kidney impairment, routine supplementation can tip into dangerous hypermagnesemia, and the supplemental upper limit for adults is only 350 milligrams a day. The biggest unsolved problem is measurement itself, because serum levels miss most insufficiency and there is still no practical, accurate biomarker of magnesium status.
Actionable Insights
Prioritize dietary magnesium, since over half of US adults fall short of the RDA (roughly 400 to 420 milligrams for men, 310 to 320 for women). Green leafy vegetables, wholegrains, nuts, and seeds are the highest-yield sources. Effect sizes worth acting on come mostly from specific groups rather than the general population.
For depression, 248 milligrams of elemental magnesium daily for six weeks lowered PHQ-9 scores by 6.0 points, a large and clinically meaningful shift. For migraine prevention, 600 milligrams of trimagnesium dicitrate daily cut attack frequency to 42 percent responders versus 16 percent on placebo. For type 2 diabetes, roughly 500 milligrams a day over 24 weeks lowered HbA1c by about 0.48 to 0.73 percent, comparable to a mild oral drug, and reduced HOMA-IR by 0.41 to 0.67 units. Blood pressure benefit is conditional: negligible in healthy normotensives, but in people with type 2 diabetes, over 300 milligrams a day for over 12 weeks dropped systolic and diastolic pressure by about 5.78 and 2.5 millimeters of mercury.
Practical rules: choose citrate or glycinate for tolerability, cap supplements near 350 milligrams a day, expect diarrhea as the first side effect, and avoid routine supplementation entirely if you have kidney impairment. There is not strong evidence on magnesium for sleep, cramps, or longevity currently.
Context and Source
- Open Access Paper: Magnesium: Hype and Health Benefits.
- Institutions: Cleveland Clinic Children’s Hospital (Cleveland, OH); Sutter Health (Santa Rosa, CA); University of Utah School of Medicine (Salt Lake City, UT); University of Texas Health San Antonio (San Antonio, TX). Country: United States.
- Journal: Current Nutrition Reports (Springer). Impact evaluation: the most recent Journal Impact Factor is approximately 8.0 (2025 JCR release, June 2026; therefore this is a Medium impact journal.